hCT-MSCs for Children With Autism Spectrum Disorder (ASD)

Summary

The purpose of this Phase 1 study is to determine the safety of one, two, and three intravenous infusions of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC), administered every two months, in children with autism spectrum disorder (ASD).

Timeline

Start

2017-06-06

Primary completion

2019-06-10

Completion

2019-06-10

Drugs

Indications